News

Jeff Fischer, MBA, discusses promising preclinical data on a cross-species, cross-strain influenza candidate with pandemic potential at the 2025 Congress of the European Society of
Clinical Microbiology and Infectious Diseases.

A surge in invasive group A Streptococcal (IGAS) infections in children marked by more virulent strains followed a reduction in cases coinciding with protective measures for the pandemic.

National Youth HIV & AIDS Awareness Day emphasizes the urgent need for culturally responsive initiatives, discoveries in hepatitis B and C, FDA fast tracks H5N1 vaccine development, and more.

Carl Schmid, executive director, HIV+Hepatitis Policy Institute, speaks to these closings.

Ross M Boyce, MD, MSc, discusses the diagnostic challenges and the need for greater awareness of tick-borne illnesses in the US, considering their potential severity.

Although there have been decreases in newly reported chronic hepatitis C cases across many demographics, the need to get people screened and given therapy in the same visit remains vital.

Jane E. Sykes, BVSc (Hons), PhD, MPH, MBA, discussed how her study revealed a wider geographic distribution of valley fever, highlighting the need for improved human surveillance.

Study shows benefit using antibiotic earlier in clinical care for gram-negative infections.

A new phase 2 trial raises questions about nirmatrelvir-ritonavir’s broader efficacy, as other studies highlight its effectiveness in reducing mortality among immunocompromised COVID-19 patients.

During these uncertain times, RAIN President and CEO Chelsea Gulden talks about the importance of taking a grassroots approach to HIV advocacy to work with young people in the local communities who are either dealing with the virus or are susceptible to it.

Investigational sa-mRNA vaccine advances to phase 1 trials for pandemic preparedness.

With the Trump administration’s plans to cease funding for Gavi, the Vaccine Alliance, as well as to reduce the US Department of Health and Human Services personnel, public health, both internationally and domestically, is going to be widely affected.

Switching from tenofovir disoproxil fumarate to besifovir dipivoxil maleate improves renal and bone health without compromising antiviral efficacy.

This open-label trial will compare the combination of the company’s therapies, bemnifosbuvir and ruzasvir, with another hepatitis C combination regimen.

Long-term clinical and economic benefits of an inclusive national HCV program targeting mothers and infants, two often overlooked populations.

Although the TB pipeline has several new agents in various phases, challenges to antimicrobial development remain. Therefore treatment adherence remains paramount.

Theratechnologies' new tesamorelin formulation provides a simplified, long-acting dosing regimen to effectively manage excess abdominal fat in adults with HIV-associated lipodystrophy.

A new analysis raises concerns over the stoppage of funding for this long-standing program, which could have major impacts on global public health for years to come.

Study uncovers the role of ploidy plasticity in fungal adaptation to fungicides, highlighting risks for human health and agricultural systems.

The 15th anniversary of the Affordable Care Act is overshadowed by threats to HIV prevention efforts, including a looming Supreme Court case that could eliminate no-cost access to preexposure prophylaxis and other preventive services. Simultaneously, deep federal cuts and restructuring have destabilized critical public health infrastructure, jeopardizing decades of progress in the fight against HIV.

Key updates from the Centers for Disease Control and Prevention on influenza activity, hospitalizations, pediatric deaths, and current trends across the United States.

A child who was not vaccinated succumbed to measles pulmonary failure. Additionally, increased cases and hospitalizations continue to grow greatly in the state.

One hospital related the evolution of resistant Acinetobacter baumannii and Pseudomonas aeruginosa in its ICU to the COVID-19 pandemic.

Development of a monoclonal antibody targeting mucormycosis, WHO’s call for improved fungal diagnostics and therapies, Bayesian dosing to optimize antimicrobial therapy, and more.

Environmental contamination plays a larger role than previously recognized, prompting calls for updated infection control strategies

Patients with suspected sepsis in the emergency department are twice as likely to survive at 28 days when antibiotics are started within 1 hour.

Sharmeen Roy, PharmD, BCPS, on artificial intelligence (AI) in improving decision-making, reducing adverse drug events on National Adverse Drug Event Awareness Day, and upcoming research on pediatric dosing at the the Congress of the European Society of Clinical Microbiology and Infectious Diseases.

Andrew Aronsohn, MD, associate professor of Medicine, University of Chicago Medical Center, discusses the hepatitis C (HCV) screen and treat plan that looks to utilize a one visit approach to get people tested and on medication in the same patient encounter.

Sharmeen Roy, PharmD, BCPS, discusses the role of AI, real-world evidence, and clinician oversight in optimizing medication dosing for ICU patients.

Lumen Bioscience’s, LMN-201, was considered safe and well-tolerated and there were no severe dose-related or serious adverse events reported.